Immunosyn Announces Interview of CEO Stephen D. Ferrone by 'CEOCFO Interviews & News'
January 31 2008 - 9:00AM
PR Newswire (US)
LA JOLLA, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Stephen D.
Ferrone, CEO and President of Immunosyn Corporation (OTC:IMYN)
(BULLETIN BOARD: IMYN) has been featured in an exclusive interview
with CEOCFO Interviews & News. The interview is posted on
http://www.immunosyn.com/news-conferences.html The interview covers
topics including Immunosyn's immediate focus, its future
development and its market potential, the shift in the
pharmaceutical industry toward biologically-derived drugs, the
science behind SF-1019, the role of Argyll Biotechnologies, LLC its
strategic partner and largest shareholder, Immunosyn's financial
picture, the US and European regulatory approval process as it
pertains to SF-1019 trials and milestones for which the public and
investors should watch. "We are pleased to be included with
CEOCFO's esteemed collection of companies. This interview offers us
the opportunity to present noteworthy announcements to brokers,
institutional managers and individual investors as part of our
strategic market communication plan," says Stephen D. Ferrone.
About CEOCFO Interviews & News http://ceocfointerviews.com/
CEOCFO Interviews & News is a bi-weekly print online
publication, marketing engine featuring publicly traded &
venture capital companies on the U.S.
(NYSE:BBNYSE:PinkNYSE:SheetsNASDAQ:BBNASDAQ:PinkNASDAQ:SheetsAMEX:BBAMEX:PinkAMEX:SheetsOTC:BBOTC:PinkOTC:Sheets)
and Canadian (TSX & TSX-V) stock exchanges, Investment &
Money Management Ideas. About Immunosyn Corporation La Jolla,
CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to
market and distribute life enhancing therapeutics. Currently, the
company has exclusive worldwide rights from its largest
shareholder, Argyll Biotechnologies, LLC, to market, sell and
distribute SF-1019, a compound that was developed from extensive
research into Biological Response Modifiers (BRMs). Argyll
Biotechnologies, LLC has initiated the process for regulatory
approval of SF-1019 in several countries and preparations for
clinical trials are underway in both the US and Europe. Research
suggests that SF-1019 has the potential to affect a number of
clinical conditions including complications from Diabetic Mellitus
such as Diabetic Neuropathy (DN) and diabetic ulcers (DU),
auto-immune disorders such as Multiple Sclerosis (MS) and
neurological disorders such as Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome
(RSD or RSDS). The above news release contains forward-looking
statements. These statements are based on assumptions that
management believes are reasonable based on currently available
information, and include statements regarding the intent, belief or
current expectations of the Company and its management. Prospective
investors are cautioned that any such forward-looking statements
are not guarantees of future performance, and are subject to a wide
range of business risks, external factors and uncertainties. Actual
results may differ materially from those indicated by such
forward-looking statements. For additional information, please
consult the Company's most recent public filings and Annual Report
on Form 10-K for its most recent fiscal year. The Company assumes
no obligation to update the information contained in this press
release, whether as a result of new information, future events or
otherwise. DATASOURCE: Immunosyn Corporation CONTACT: Bill Kraus,
Lisa Baker, or Devon Blaine, +1-310-360-1499, Fax, +1-310-360-1498,
, all of The Blaine Group Web site:
http://www.immunosyn.com/news-conferences.html
http://ceocfointerviews.com/
Copyright